8-K: EyePoint's DURAVYU Phase 3 Trials Get Positive DSMC Nod

EyePoint Pharmaceuticals announced a positive recommendation from its independent Data Safety Monitoring Committee for its pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration.

Summary

• The independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of EyePoint Pharmaceuticals' ongoing pivotal Phase 3 program for DURAVYU in wet age-related macular degeneration (wet AMD).
• The DSMC recommended that both the LUGANO and LUCIA trials continue as planned, with no modifications to the protocol.
• Masked safety data consistently shows no safety signals, which is consistent with previous clinical trials for DURAVYU.
• As of the September 29, 2025 data cutoff for the DSMC review, all patients across the LUGANO and LUCIA trials had reached their Week 8 visit, receiving their initial DURAVYU dose, and approximately 25% of those patients had received their second planned dose at Week 32.
• LUGANO and LUCIA are randomized, double-masked, aflibercept-controlled, non-inferiority Phase 3 trials assessing DURAVYU's efficacy and safety in over 900 enrolled patients with active wet AMD, including both treatment-naïve and treatment-experienced individuals.
• Patients are randomized 1:1 to receive either DURAVYU 2.7mg every six months or aflibercept on-label as control.
• The primary endpoint of the Phase 3 pivotal trials is non-inferiority in the average change in best corrected visual acuity (BCVA) at weeks 52 and 56 compared to baseline.
• Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections, and anatomical results as measured by optical coherence tomography (OCT).

Sentiment

Score: 8

Explanation: The positive recommendation from the DSMC for the continuation of pivotal Phase 3 trials without modification, coupled with consistent favorable safety data, is a strong positive signal for DURAVYU's development. This significantly reduces clinical risk and maintains the timeline for topline data, which is crucial for investor confidence in a clinical-stage biopharmaceutical company.

Positives

• Received a positive recommendation from the independent Data Safety Monitoring Committee (DSMC) for the pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD.
• The DSMC recommended the continuation of both trials as planned, with no protocol modifications, indicating no significant safety concerns.
• Masked safety data consistently shows no safety signals, aligning with observations from prior DURAVYU clinical trials.
• DURAVYU is designed for sustained release for at least six months, potentially offering a significant reduction in treatment burden compared to the current standard-of-care.
• Vorolanib, the active ingredient in DURAVYU, is a differentiated tyrosine kinase inhibitor (TKI) with a novel multi-mechanism of action, targeting both VEGF-mediated vascular permeability and IL-6 mediated inflammation.
• Previous DAVIO 2 Phase 2 trial in wet AMD demonstrated an impressive 88% reduction in treatment burden six months after treatment with DURAVYU, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection.
• No safety signals have been observed in over 190 patients across four completed clinical trials, including three Phase 2 trials.
• DURAVYU is also being advanced for Diabetic Macular Edema (DME), with first patient dosing in Phase 3 trials (COMO and CAPRI) expected in the first quarter of 2026, following positive Phase 2 VERONA trial results.

Risks

• Uncertainties exist regarding the timing, progress, and results of the Company's clinical development activities, including DURAVYU.
• There are uncertainties and potential delays related to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU's commercialization.
• The Company may incur unanticipated costs and expenses.
• The Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data could be observed during clinical trials.
• Uncertainties are present regarding the regulatory authorization or approval process and available development and regulatory pathways for product candidates.
• Changes in the regulatory environment, including disruptions at the FDA due to workforce reductions or inadequate funding, could impact development.
• Changes in U.S. and international trade policies could affect operations.
• There is a risk of changes in expected or existing competition.
• The success of current and future license agreements is not guaranteed.
• The Company depends on contract research organizations and other outside vendors and service providers.
• Product liability risks are inherent in the pharmaceutical industry.
• The Company's operations are subject to the impact of general business and economic conditions.
• Protecting intellectual property and avoiding intellectual property infringement are ongoing challenges.
• Retention of key personnel is crucial for the Company's success.
• Delays, interruptions, or failures in the manufacture and supply of product candidates could occur.
• The availability of and the need for additional financing are potential concerns.
• The Company's ability to obtain additional funding to support its clinical development programs is uncertain.
• Uncertainties exist regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties remain regarding the FDA warning letter pertaining to the Company's Watertown, MA manufacturing facility.

Future Outlook

EyePoint Pharmaceuticals expects to report topline 56-week data for the LUGANO trial in mid-2026, with LUCIA data to follow closely thereafter. The Company anticipates initiating first patient dosing in Phase 3 trials for DURAVYU in diabetic macular edema (DME) (COMO and CAPRI) in the first quarter of 2026. EyePoint believes DURAVYU is well-positioned to be the first-to-market among investigational sustained release treatments for wet AMD and a unique tyrosine kinase inhibitor (TKI) in development for DME, potentially addressing both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers.

Management Comments

• "We are pleased to receive our second consecutive positive recommendation from the DSMC for our pivotal wet AMD program. Now that all patients are past initial dosing and a growing number have received redosing, this recommendation strengthens our confidence in DURAVYU’s consistent, favorable safety profile observed across its robust development history." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.
• "As we advance toward topline data starting in mid-2026, we remain focused on continued clinical trial execution and regulatory preparedness to support our ultimate goal of delivering DURAVYU to patients as expeditiously as possible." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.

Industry Context

Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss, requiring continuous and frequent treatment, typically every two months, with current standard-of-care anti-VEGF treatments. This high treatment burden often leads to patient noncompliance and potential vision loss. DURAVYU, with its potential for 6-month sustained delivery and a multi-mechanism of action targeting both VEGF and IL-6, aims to significantly reduce this burden and offer a differentiated therapeutic approach in a market with substantial unmet needs.

Comparison to Industry Standards

• Current standard-of-care anti-VEGF treatments for wet AMD, such as aflibercept, are typically dosed on average every two months under a treat-and-extend protocol.
• DURAVYU is being evaluated for 6-month redosing, which, if approved, would represent a significant reduction in treatment frequency compared to existing therapies, potentially improving patient compliance and reducing healthcare system burden.
• Unlike many current large molecule anti-VEGF treatments that primarily target VEGF, DURAVYU's vorolanib is a tyrosine kinase inhibitor (TKI) with a novel multi-mechanism of action, targeting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, and potentially inhibiting PDGF for antifibrotic benefits.
• The LUGANO and LUCIA trials are notable as the only sustained release wet AMD pivotal Phase 3 trials evaluating 6-month redosing over two years.
• Data from the DAVIO 2 Phase 2 trial in wet AMD demonstrated an 88% reduction in treatment burden six months after DURAVYU treatment, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection, suggesting a potentially superior dosing interval compared to standard of care.

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Company's Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders: Positive news regarding clinical trial progression and a favorable safety profile could increase investor confidence and potentially lead to share price appreciation by de-risking the pipeline.
• Patients with Wet AMD: Potential for a new, less burdensome treatment option with 6-month dosing, which could improve compliance and visual outcomes compared to current frequent injection regimens.
• Physicians: A new treatment option that could simplify patient management with significantly less frequent intravitreal injections.
• Healthcare System: Potential for reduced treatment burden and associated costs if 6-month dosing is achieved, leading to more efficient resource utilization.

Next Steps

• Continue clinical trial execution for the LUGANO and LUCIA Phase 3 trials.
• Focus on regulatory preparedness for DURAVYU.
• Report topline 56-week data for the LUGANO trial in mid-2026.
• Report LUCIA data closely following the LUGANO results.
• Initiate first patient dosing in Phase 3 trials (COMO and CAPRI) for DURAVYU in Diabetic Macular Edema (DME) in the first quarter of 2026.

Key Dates

Recommendation

The positive DSMC recommendation for the continuation of pivotal Phase 3 trials for DURAVYU in wet AMD, with no safety signals and no protocol modifications, significantly de-risks the clinical development pathway. This news reinforces the potential for DURAVYU to become a differentiated, sustained-delivery treatment, addressing a major unmet need in a large market. The consistent safety profile and the prospect of 6-month dosing, along with the multi-mechanism of action, position EyePoint favorably against existing therapies. The upcoming topline data in mid-2026 and the initiation of DME Phase 3 trials in Q1 2026 provide clear catalysts. While general risks inherent in drug development remain, this update is a strong positive indicator for the company's pipeline and future commercial prospects, making it an attractive investment for long-term growth.

Keywords

EyePoint Pharmaceuticals, EYPT, DURAVYU, wet AMD, age-related macular degeneration, Phase 3, clinical trials, LUGANO, LUCIA, Data Safety Monitoring Committee, DSMC, vorolanib, tyrosine kinase inhibitor, TKI, Durasert E, sustained delivery, retinal diseases, ophthalmology, anti-VEGF, aflibercept, diabetic macular edema, DME